Tuberculosis: Common Questions and Answers

Area of Science:

• Infectious Diseases
• Public Health
• Microbiology

Background:

• Tuberculosis (TB) remains a significant global health challenge, causing millions of infections and deaths annually.
• Latent TB infection (LTBI), an asymptomatic state caused by Mycobacterium tuberculosis, affects millions in the US and can progress to active disease in 5-10% of individuals.
• Early detection and treatment of LTBI and active TB disease are critical for public health.

Purpose of the Study:

• To outline current recommendations for testing, diagnosis, and treatment of latent tuberculosis infection (LTBI) and active TB disease.
• To emphasize the importance of reporting suspected and confirmed cases of TB to health departments.
• To provide guidance on preferred treatment regimens for LTBI and drug-susceptible TB disease.

Main Methods:

• Review of U.S. Preventive Services Task Force guidelines for LTBI screening.
• Description of diagnostic procedures including interferon-gamma release assays, tuberculin skin testing, chest radiography, and sputum collection.
• Summary of recommended treatment regimens for LTBI and drug-susceptible TB disease.

Main Results:

• The U.S. Preventive Services Task Force recommends testing individuals at increased risk for LTBI.
• Periodic retesting of healthcare professionals for LTBI is not recommended due to similar incidence rates to the general population.
• Reporting of all suspected and confirmed LTBI and TB disease cases is mandatory.

Conclusions:

• Prompt diagnosis and treatment of LTBI and active TB disease are essential to prevent progression and transmission.
• Specific treatment regimens are recommended for LTBI and drug-susceptible TB disease.
• Consultation with TB experts is vital for managing drug-resistant TB cases.